AmbioPharm To Utilize YMC Twin-Column Chromatography in Large Scale Peptide Production

29 March 2023 | Wednesday | News

AmbioPharm, a worldwide leader in peptide API CDMO services, announces the acquisition of new, disruptive, peptide purification technology developed by YMC which leverages several of YMC’s patented1 twin-column purification processes. Twin-column chromatography or Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) is a continuous chromatographic process which collects a high purity center cut fraction and internally recycles mixed impurity/product-containing side fractions all while loading fresh feed and discarding impurities (see diagram).

This technology offers several advantages over traditional batch purification including:

  • Higher peptide purity
  • Increased yield
  • Decreased solvent requirements
  • Time savings
  • Significant reduction of fraction collection, storage, QC, blending, and reprocessing

As a leader in peptide manufacturing and development, AmbioPharm is continuously upgrading equipment and technologies, especially those that can improve our capacity and sustainability. Using our expertise in peptide synthesis, we are able to tackle both simple and complex peptide projects with a proven history of success at research, clinical, and commercial scales.

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close